Workboat Indexes

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

54.40 -0.30 (-0.55%)

Streaming Delayed Price Updated: 2:20 PM EDT, Mar 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

44 45 Next >

GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗

September 11, 2024

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...

Via Benzinga

FDA Battles Backlog of Drug Factory Inspections Since COVID-19 ↗

September 06, 2024

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

Via Benzinga

GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug ↗

September 06, 2024

GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.

Via Benzinga

Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets ↗

August 23, 2024

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite concerns, experts predict limited financial impact on companies like Pfizer,...

Via Benzinga

Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings ↗

July 29, 2024

The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.

Via Benzinga

Topics Economy

Is GSK a Top-Value Stock Right Now? ↗

July 17, 2024

GSK, a multinational pharma company, scans as a bargain.

Via The Motley Fool

10 Health Care Stocks Whale Activity In Today's Session ↗

August 19, 2024

Via Benzinga

Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk ↗

August 16, 2024

A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules ↗

August 13, 2024

Pharmaceutical companies, researchers, and patient groups are voicing concerns over new EU regulations that could hinder rare disease treatment development by imposing stricter guidelines on medical...

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

August 12, 2024

Via Benzinga

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows

August 07, 2024

Via Investor Brand Network

Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%

August 06, 2024

From Myriad Genetics, Inc.

Via GlobeNewswire

Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

August 06, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:PFE),(NYSE:LLY),(NYSE:GSK),(NYSE:NVO) EQNX::TICKER_END

Via FinancialNewsMedia

Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033

August 06, 2024

From FN Media Group LLC

Via GlobeNewswire

Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again. ↗

August 05, 2024

Moderna sustained a rare downgrade on Monday following its guidance cut for the year.

Via Investor's Business Daily

Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer ↗

August 02, 2024

Moderna cuts its 2024 sales forecast due to weaker demand for COVID-19 vaccines. Sales now expected between $3B-$3.5B, down from $4B. Analysts adjust price targets, citing competitive pressures from...

Via Benzinga

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

August 01, 2024

From GSK plc

Via Business Wire

British Pharma Giant GSK's Blockbuster Shingles And Respiratory Syncytial Virus Vaccine Q2 Sales Miss Expectations, Cuts Annual Vaccine Revenue Guidance ↗

July 31, 2024

GSK reported Q2 sales of $9.95 billion, beating estimates of $9.66 billion. Specialty Medicine sales rose 20%, driven by strong HIV, Respiratory/Immunology, and Oncology performance. Core EPS of $1.10...

Via Benzinga

Topics Earnings

GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss ↗

July 31, 2024

The company, however, raised its sales and earnings outlook for the year.

Via Investor's Business Daily

GSK Stock Earnings: GSK Beats EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

GSK stock results show that GSK beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday? ↗

July 31, 2024

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting.

Via Benzinga

Topics Economy

GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests ↗

July 26, 2024

New research suggests that GSK's Shingrix vaccine may reduce dementia risk, potentially revolutionizing treatment for older adults. The study, involving 200,000 people, indicates a significant...

Via Benzinga

Wall Street Remains On Track For AMD-Led Rebound Ahead Of Fed Decision, Meta Earnings: Analyst Says 'The Bull Tends To Remain' Despite Near-Time Volatility ↗

July 31, 2024

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro Devices, Inc.‘s (NASDAQ:AMD)

Via Benzinga

Topics Economy

Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial ↗

July 23, 2024

ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...

Via Benzinga

3 Stocks Under $10 With the Potential for Massive Gains ↗

July 22, 2024

Discover the growth potential of top small-cap stocks in the consumer finance, healthcare equipment and pharmaceutical industries.

Via InvestorPlace

Top Research Reports For Apple, Lowe's & Shopify ↗

July 17, 2024

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and...

Via Talk Markets

European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment ↗

July 17, 2024

European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.

Via Benzinga

3 Top Cancer Treatment Stocks to Buy Now ↗

July 17, 2024

These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term.

Via InvestorPlace

Positive News is Driving This Cancer Drug Maker’s Stock Higher

July 15, 2024

IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather

Via MarketBeat

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Workboat Indexes

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Crosby subsidiaries file for Chapter 11 restructuring

Coast Guard seeks industry input for light icebreaker cutter program

Bulk carrier grounds after collision on Mississippi River

Draftsmen on strike at Bath Iron Works